Cite this: *New J. Chem.*, 2017, 41, 1940

Trinuclear (aminonitrone)Zn^{II} complexes as key intermediates in zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles†

Dmitrii S. Bolotin,^a Mikhail V. Il'in,^a Alexander S. Novikov,^a Nadezhda A. Bokach,^a Vitalii V. Suslonov^b and Vadim Yu. Kukushkin^{*a}

Aliphatic and aromatic amidoximes $\text{RC}(\text{NH}_2)=\text{NOH}$ ($\text{R} = \text{Et}$, $t\text{Bu}$, Ph , $o\text{-ClC}_6\text{H}_4$) react with $\text{Zn}(\text{OAc})_2 \cdot 2\text{H}_2\text{O}$ in Me_2CO giving $[\text{Zn}(\text{OAc})_2\{\text{RC}(\text{NH}_2)=\text{NOH}\}_2]$ complexes bearing *N*-bound amidoximes, which are involved in a moderate strength (7.3–11.9 kcal mol^{−1} by the DFT calculations) intramolecular resonance-assisted hydrogen bonding between the oxime HO group and the oxo group of the acetate ligand. The complexes $[\text{Zn}(\text{OAc})_2\{\text{RC}(\text{NH}_2)=\text{NOH}\}_2]$ react with excess $\text{Zn}(\text{OTf})_2$ in acetone accomplishing trinuclear species $[\text{Zn}_3(\mu_2\text{-OAc})_2(\mu_2\text{-RC}(\text{NH}_2)=\text{N}(\text{H})\text{O})_4(\text{H}_2\text{O})_6](\text{OTf})_4$ featuring both *O*-ligated amidoximes—stabilized in the aminonitrone tautomeric form—and bridging acetate ligands. The aminonitrone trinuclear species were also prepared directly *via* the reaction of the amidoximes with $\text{Zn}(\text{OTf})_2$ in EtOAc; ethyl acetate in this reaction plays the role of the acetate donor and OAc^- is generated *in situ* *via* Zn^{II}-mediated hydrolysis of EtOAc. Although $[\text{Zn}(\text{OAc})_2\{\text{RC}(\text{NH}_2)=\text{NOH}\}_2]$ are inactive toward dimethylcyanamide, the $[\text{Zn}_3(\mu_2\text{-OAc})_2(\mu_2\text{-RC}(\text{NH}_2)=\text{N}(\text{H})\text{O})_4(\text{H}_2\text{O})_6](\text{OTf})_4$ complexes readily react with Me_2NCN giving, as a result of Zn^{II}-mediated amidoxime–cyanamide coupling, the *O*-carbamidine amidoxime complexes $[\text{Zn}(\text{OTf})_2\{\text{RC}(\text{NH}_2)=\text{NOC}(\text{NMe}_2)=\text{NH}\}_2]$. All synthesized compounds were characterized by HRESI-MS, FTIR, ¹H-, CP-MAS TOSS ¹³C{¹H}-, and ¹³C{¹H} NMR, and additionally by single-crystal X-ray diffraction for eight species. Different types of non-covalent interactions in the obtained solid-state structures were studied by DFT calculations (M06-2X/6-311+G(d,p) level of theory) and topological analysis of the electron density distribution within the formalism of Bader's theory (QTAIM method).

Received 9th November 2016,
Accepted 15th January 2017

DOI: 10.1039/c6nj03508f

rscl.njc

Introduction

The zinc(II)-mediated reaction between amidoximes and nitriles¹ is among the most facile and expedient routes for the synthesis of 1,2,4-oxadiazoles – a class of heterocycles that exhibit a wide range of biomedical² (*e.g.*, antibacterial,³ antibiotic,⁴ antimalarial,⁵ anticancer,⁶ anticonvulsant,⁷ immunomodulating⁸ and antihistaminic⁹) properties. These ring systems also act as active antihypertensive agents,¹⁰ selective inhibitors

of 11β-hydroxysteroid dehydrogenase,¹¹ dopamine D3 receptor ligands,¹² glycogen phosphorylase inhibitors,¹³ and elective agonists of free fatty acid receptor,¹⁴ and serve as useful precursors for materials science for mastering liquid crystals,¹⁵ nanoporous networks,¹⁶ and insensitive energetic materials.¹⁷

Recent synthetic works^{1a,18} helped to obtain some data partially explaining the mechanism of heterocyclization. In particular, intermediates **A** and **B** (Scheme 1) in the reaction between R_2NCN and $\text{R}'(\text{NH}_2)\text{C}=\text{NOH}$ in the presence of zinc(II) in undried EtOAc were trapped and identified. These data allowed the assumption that the overall reaction starts from the Zn^{II}-mediated amidoxime–nitrile coupling. However, black-boxed intermediate zinc(II) complexes featuring coordinated amidoximes and/or nitriles were neither isolated/characterized nor identified *in situ* by physicochemical methods.

Being interested in understanding the detailed mechanism of Zn^{II}-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles^{1a,18} and in further development of coordination chemistry of amidoximes ($\rightleftharpoons$ aminonitrone) (for our review on this subject see ref. 19), we synthesized novel zinc(II) species featuring amidoximes and studied their reactivity toward

^a Institute of Chemistry, Saint Petersburg State University, Universitetskaya Nab., 7/9, Saint Petersburg, Russian Federation. E-mail: v.kukushkin@spbu.ru

^b Center for X-ray Diffraction Studies, Saint Petersburg State University, Universitetskii Pr., 26, Saint Petersburg, Russian Federation

† Electronic supplementary information (ESI) available: Analytical and spectroscopy data; the structures of the *O*-iminoacylated oximes; spectra of **2a–d**, **[3a–d](OTf)₄**, **[4a–c](OTf)₂**, and **[5a–d](OTf)**; crystal data for **2a–c**, **[3a](OTf)₄**, **[4b](OTf)(EtOH)(OTf)**, **[4c](OTf)₂**, **[5a](OTf)**, and **[5d](OTf)**; theoretical study of bonding situation in solid state structures of **2** and **[4](OTf)₂**, calculated Wiberg bond indices for selected bonds in **2a–c**; Cartesian atomic coordinates of model structures; crystallographic information files for **2a–c**, **[3a](OTf)₄**, **[4b](OTf)(EtOH)(OTf)**, **[4c](OTf)₂**, **[5a](OTf)**, and **[5d](OTf)**. CCDC 1503999–1504006. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6nj03508f

Scheme 1 Simplified mechanism of zinc(II)-mediated generation of 1,2,4-oxadiazoles.

Me_2NCN as a representative of cyanamides. The main idea of this work was to obtain experimental data fully explaining the mechanism of zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles to provide a solid background for rational choice of reactants and reaction conditions.

The scenario of this study was as follows. Firstly, we synthesized zinc(II) amidoxime species and determined ligand coordination patterns (amidoxime and aminonitrone forms) and verified the structures of these complexes both experimentally and theoretically. Secondly, we studied the reactivity of the (amidoxime) Zn^{II} and (aminonitrone) Zn^{II} complexes toward Me_2NCN as a model cyanamide substrate. Based on all these data we, thirdly, described the mechanism of zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles. All the obtained data along with the corresponding discussions are consistently disclosed in sections that follow.

Results and discussion

Generation of zinc(II) amidoxime and aminonitrone complexes

As starting materials for the generation of zinc(II) amidoxime and aminonitrone complexes we used the aromatic and aliphatic amidoximes $\text{RC}(\text{NH}_2)=\text{NOH}$ ($\text{R} = \text{Ph}$ **1a**, $o\text{-ClC}_6\text{H}_4$ **1b**, Et **1c**, $t\text{-Bu}$ **1d**) and, as sources of zinc(II), the salts $\text{Zn}(\text{OTf})_2$ and $\text{Zn}(\text{OAc})_2 \cdot 2\text{H}_2\text{O}$. We also applied Me_2CO and EtOAc as solvents in our synthetic experiments to understand the mysterious effect of ethyl acetate on the facilitation of the Zn^{II} -mediated reaction.^{1a}

We started our experiments under conditions, which were applied for synthetically optimized Zn^{II} -mediated amidoxime-cyanamide coupling.^{1a} When undried EtOAc was employed as a solvent in the reaction between **1a–d** and $\text{Zn}(\text{OTf})_2$ (Scheme 2, c2), we observed the generation of trinuclear complexes $[\mathbf{3a-d}](\text{OTf})_4$. We varied molar ratios between **1a–d** and $\text{Zn}(\text{OTf})_2$ from 1 : 1 to 6 : 1, including 2 : 1, and found that the trinuclear complexes are formed in all these combinations. The highest yields of $[\mathbf{3a-d}](\text{OTf})_4$ (70–87%) were achieved when the molar ratio between **1a–d** and $\text{Zn}(\text{OTf})_2$ was 4 : 3 and the reaction mixture was refluxed for 30 min in EtOAc (C2). We believe that in $[\mathbf{3a-d}](\text{OTf})_4$, two bridging OAc^- ligands are derived from Zn^{II} -mediated hydrolysis of EtOAc; a relevant metal-mediated

hydrolysis of ethyl acetate has previously been repeatedly reported (see, for example, ref. 20).

Concurrently, treatment of **1a–d** with $\text{Zn}(\text{OTf})_2$ in a molar ratio 2 : 1 in acetone either at RT or 50 °C for 1 day gives a broad spectrum of products that we failed to separate. After keeping the reaction mixture for 1 week at 20–25 °C we observed the formation of $[\mathbf{1a-dH}](\text{OTf})$ in the solution along with some amount of zinc-containing precipitate.

We assumed that the presence of acetate favors the generation of the trinuclear complexes. Accordingly, **1a–d** were treated with $\text{Zn}(\text{OAc})_2 \cdot 2\text{H}_2\text{O}$ in a molar ratio 2 : 1 in acetone at 50 °C and we observed the fast (5 min) formation of **2a–d** that were isolated in 75–82% yields (Scheme 2, a2). Complexes **2a–d** were easily transformed into the corresponding $[\mathbf{3a-d}](\text{OTf})_4$ when **2a–d** reacted with 2 equiv. of $\text{Zn}(\text{OTf})_2$ and 2 equiv. of **1a–d** in undried acetone for 5 min at 50 °C (b2). The reverse process—which includes the transformation of $[\mathbf{3a-d}](\text{OTf})_4$ to **2a–d**—was not realized and the addition of the corresponding amidoxime (2 equiv.) and NaOAc (4 equiv.) to $[\mathbf{3a-d}](\text{OTf})_4$ in acetone (5 min, 50 °C or 1 d, RT) led to amorphous zinc hydroxides and $[\mathbf{1a-dH}](\text{OAc})$.

Zinc(II)-mediated amidoxime-cyanamide coupling

In order to study the reactivity of the zinc(II)-bound oximes, we reacted complexes **2a–d** and $[\mathbf{3a-d}](\text{OTf})_4$ with dimethylcyanamide as a model nitrile substrate. When complexes $[\mathbf{3a-d}](\text{OTf})_4$ were treated with 4 equiv. of Me_2NCN (EtOAc, RT, 3 h), the reaction yielded either imino complexes $[\mathbf{4a-c}](\text{OTf})_2$ ($\text{R} = \text{Ph}$, $o\text{-ClC}_6\text{H}_4$, Et; Scheme 2, d2), or iminium salt $[\mathbf{5d}](\text{OTf})$ ($\text{R} = t\text{-Bu}$; d2 and f2) in excellent (93–98%) yields. Complex $[\mathbf{4d}](\text{OTf})_2$ was not obtained due to the steric hindrance of the bulky $t\text{-Bu}$ group, which precluded the formation of the chelated complex and gave only uncomplexed $[\mathbf{5d}](\text{OTf})$. Imino complexes $[\mathbf{4a-c}](\text{OTf})_2$ and salt $[\mathbf{5d}](\text{OTf})$ were also generated by the direct reaction of **1a–d** with Me_2NCN and $\text{Zn}(\text{OTf})_2$ (EtOAc, RT, 3 h; e2). The yields of $[\mathbf{4a-c}](\text{OTf})_2$ and $[\mathbf{5d}](\text{OTf})$ obtained *via* route e2 are comparable with the corresponding overall yields determined for routes c2 and d2 (approx. 70–80%). Complexes **2a–d** do not react with Me_2NCN at RT even for 24 h and a mixture of yet unidentified products was formed when the reaction was attempted at 50 °C for 3 h.

In our previous study, we demonstrated that substituted cyanamides and nitriles RCN ($\text{R} = \text{Alk}$, Ar, NR_2) are involved in the coupling with amidoximes in the presence of ZnCl_2 achieving the complexes $[\text{ZnCl}_2\{\text{N}(\text{H})=\text{C}(\text{R})\text{ONC}(\text{NH}_2)\text{R}'\}]$ and this reaction is metal-mediated.^{1a} Herein, we demonstrate that aminonitrone trinuclear species $[\mathbf{3a-d}](\text{OTf})_4$ can also be involved in the zinc(II)-mediated coupling with Me_2NCN and (aminonitrone) Zn^{II} complexes, *viz.* $[\mathbf{3a-d}](\text{OTf})_4$, serve as key intermediates of the coupling.^{1a}

Our observations provide a background for a deeper understanding of the mechanism of Zn^{II} -mediated amidoxime-cyanamide coupling. Insofar as **2a–d** and $[\mathbf{3a-d}](\text{OTf})_4$ demonstrated different reactivities toward Me_2NCN , one can assume a strong effect of the coordination pattern of the amidoxime on the reaction. Thus, in **2a–d**, the *N*-coordinated amidoxime—which

Scheme 2 The studied reactions.

is involved in the formation of intramolecular resonance-assisted hydrogen bonding (RAHB; for recent works on this type of hydrogen bonding see ref. 21) between the oxime HO group and the oxo group of the acetate ligand—does not react with Me_2NCN . In $[3 \text{ a-d}](\text{OTf})_4$, *O*-coordinated amidoxime in its aminonitrone form reacted with Me_2NCN under mild conditions (RT, 3 h). The latter observation is in agreement with the theoretical calculation data, which demonstrated that oxime–nitrile coupling proceeds *via* the aminonitrone form of the nucleophile.²²

Analytical and spectroscopy data

Complexes **2a–d**, $[3 \text{ a-d}](\text{OTf})_4$, $[4 \text{ a-c}](\text{OTf})_2$, and salts $[5 \text{ a-d}](\text{OTf})$ gave satisfactory C, H, and N elemental analysis results for the proposed formulas, and these species were also characterized by high-resolution ESI-MS, FTIR, ^1H -, and CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ (for poorly soluble **2a–d**, $[3 \text{ a-d}](\text{OTf})_4$, and $[5 \text{ d}](\text{OTf})$ or $^{13}\text{C}\{^1\text{H}\}$ NMR spectroscopy (for $[4 \text{ a-c}](\text{OTf})_2$ and $[5 \text{ a-c}](\text{OTf})$ exhibiting sufficient solubility) and additionally by single-crystal X-ray diffraction for eight species (**2a–c**, $[3 \text{ a}](\text{OTf})_4$, $[4 \text{ b}](\text{OTf})(\text{EtOH})(\text{OTf})$, $[4 \text{ c}](\text{OTf})_2$, $[5 \text{ a}](\text{OTf})$, and $[5 \text{ d}](\text{OTf})$).

For a detailed description of the characterization see the ESI.† Briefly, the IR spectra of **2a–d**, $[3 \text{ a-d}](\text{OTf})_4$, and $[4 \text{ a-c}](\text{OTf})_2$, exhibit one $\nu(\text{C}=\text{N})$ band in the range $1678\text{--}1638\text{ cm}^{-1}$, which is specific to amidoximes.¹⁹ The spectra of **2a–d** and $[3 \text{ a-d}](\text{OTf})_4$ also display three strong to very strong bands in the region $1608\text{--}1340\text{ cm}^{-1}$ from the $\nu(\text{C}=\text{O})$ of the ligated acetate group. A characteristic feature of the ^1H NMR spectra of **2a–d** and $[3 \text{ a-d}](\text{OTf})_4$ recorded in $(\text{CD}_3)_2\text{CO}$ is the absence of the OH and

ONH signals due to a fast exchange with water protons. Another feature is the availability of broad singlets attributed to the NH_2 resonances at 6.40–5.29 (for **2a–d**) and 8.48–7.93 ppm (for $[3 \text{ a-d}](\text{OTf})_4$). The low-field shift of the signal in the spectra of $[3 \text{ a-d}](\text{OTf})_4$ is probably due to the positive charge on the HNCNH_2 moiety provided by the stabilization of **1a–d** ligands in the aminonitrone form.

X-ray structure determination, QTAIM and NBO analysis of the bonding

(i) **The structures of the trinuclear complexes and aminonitrone coordination pattern.** In the molecular structure of trinuclear $[3 \text{ a}](\text{OTf})_4$, the coordination polyhedra of the zinc(II) centers display typical octahedral geometries (Fig. 1). All bond angles around the zinc(II) centers range from $73.29(16)$ to $105.95(17)^\circ$, the Zn–O [$1.944(4)\text{--}2.1460(4)\text{ \AA}$] and N(2)–C(1) [$1.319(10)\text{--}1.330(8)\text{ \AA}$] bonds are normal single bonds,²³ whereas the O(1)–N(2) distances [$1.344(7)\text{--}1.357(7)\text{ \AA}$] are shorter than the usual O–N^{sp} bonds and typical for *O*-ligated amidoximes in the aminonitrone form.¹⁹ The N(1)–C(1) distance values [$1.298(8)\text{--}1.309(8)\text{ \AA}$] indicate an intermediate order between typical single and double bonds,²³ which reflects the amide character of these bonds. The carbamidoxime groups are in the *Z*-configuration. The intermolecular H-bonds are between the aminonitrone NH atom and the O atom of one of the triflate [$\text{N}\cdots\text{O}$ $2.749\text{--}2.789\text{ \AA}$; $\text{N-H}\cdots\text{O}$ $155.11\text{--}167.27^\circ$]. Hydrogen bonds between the amide H atoms and the triflate O atoms and between the ligated H_2O and the triflate counter-ions were observed. It is noteworthy

Fig. 1 The structure of $[3a]^{4+}$ showing the atomic numbering scheme. Thermal ellipsoids are given at the 50% probability level.

that trinuclear complexes bearing bridging carboxylate ligands linking the three zinc centers in the $\{Zn(\mu_2-O_2CR)Zn(\mu_2-O_2CR)Zn\}$ ($R = Me, Ph$) moieties are known (for recent examples see ref. 24).

Amidoximes and their deprotonated forms possess three nucleophilic centers, *viz.* two N- and one O atoms, therefore several types of coordination modes for these ligands can be realized. In our recent review,¹⁹ we analyzed the existing data on amidoxime coordination, verified nine patterns, and led to the conclusion that *N*-binding (as in **2a–d**) is the conventional coordination pattern. The binding in the aminonitrone form, *viz.* $[M]\{ON(H)=C(NR_2)R'\}$ or $[M]_2\{\mu_2-ON(H)=C(NR_2)R'\}$ (Fig. 2) less common.

If the former type (A) of coordination was documented for U^{VI} ,²⁵ Pu^{IV} ,²⁶ Ge^{IV} ,¹⁹ Sn^{IV} ,¹⁹ and Fe^{III} ,^{19,27} species, the latter type (B)—which we observed in $[3a-d](OTf)_4$ —is substantially less abundant and it was previously observed only for a molybdenum(vi) center.^{19,28} The difference in bonding pattern can be rationalized by the application of Pearson's HSAB principle²⁹ and charge considerations. Accordingly, the aminonitrone form coordinates to the harder and highly charged $\{Zn_3(OAc)_2\}^{4+}$ moiety *via* a “hard” and negatively charged oxygen center, whereas neutral amidoximes tend to ligate to the neutral $Zn(OAc)_2$ species, as in **2a–d**, *via* a relatively “soft” nitrogen center. An additional stabilization of **2a–d** by resonance-assisted hydrogen bonding (see below) should be taken into account.

(ii) The structures of monomeric 2a–c involving resonance-assisted hydrogen bonding. In the molecular structures of **2a–c**, the coordination polyhedra exhibit a distorted tetrahedral geometry (Fig. 3). All bond angles around the zinc(II) centers range from $93.58(5)$ to $122.11(7)^\circ$. The Zn–O distances $[1.9538(19)–1.9975(19) \text{ \AA}]$

Fig. 2 O-Coordinated amidoxime moiety.

Fig. 3 The molecular structure of **2a** showing the atomic numbering scheme. Thermal ellipsoids are given at the 50% probability level.

are specific for the $(\text{acetate})Zn^{II}$ bonds.³⁰ The Zn–N bond lengths $[1.9890(17)–2.0043(18) \text{ \AA}]$ exhibit values characteristic for $(\text{oxime})Zn^{II}$ bonds.^{30a} The O(1)–N(2) distances $[1.414(12)–1.425(2) \text{ \AA}]$ are typical for *N*-ligated amidoximes.¹⁹ The N(2)–C(1) $[1.334(2)–1.342(4) \text{ \AA}]$ and O(1)–C(2) $[1.328(2)–1.366(4) \text{ \AA}]$ bonds are normal single bonds.²³ The N(1)–C(1) distances $[1.296(4)–1.3042(18) \text{ \AA}]$ indicate an intermediate order between typical single and double bonds,²³ which reflects the amide character of these bonds. The carbamidoxime groups are in the *Z*-configuration.

Intramolecular resonance-assisted hydrogen bonding (RAHB) between the H atom of the HO-group and the O atom of the acetate ($O(1) \cdots O(2) 2.600–2.696 \text{ \AA}$; $O(1)–H \cdots O(2) 158.16–173.44^\circ$) was identified and this hydrogen bonding can be responsible for additional stabilization of the structure with the monodentately coordinated amidoxime. Similar RAHB stabilized structures were reported for $(\text{AcO})M^{II}$ ($M = Mn$,³¹ Zn ,^{30b,31} Ni ³²) complexes bearing bidentate *N,N'*-coordinated 2-pyridine amidoxime.

Zinc(II) complexes with terminal *N*-coordinated amidoximes, are known,¹⁹ while the previously reported complexes comprise bidentately coordinated ligands in which at least one coordinating group is an *N*-coordinated amidoxime moiety (Fig. 4, C).^{1a,19,30b,c,31,33}

Our complexes **2a–d** are the first examples of Zn^{II} -complexes bearing monodentately *N*-coordinated amidoxime, but one should take into account that this binding mode is rather specific as it is supported by RAHB (Fig. 4, D).

Fig. 4 N-Coordinated amidoxime moiety.

Fig. 5 Contour line diagram of the Laplacian distribution $\nabla^2\rho(r)$, bond paths and selected zero-flux surfaces for RAHB O-H...O in **2a**. Bond critical points (3, -1) are shown in blue and nuclear critical points (3, -3) in pale brown, length unit - Å.

The topological analysis of the electron density distribution within the formalism of Bader's theory (QTAIM method)³⁴ for **2a-c** (this approach has already been successfully used by us in studies of the non-covalent interactions and properties of coordination bonds in various transition metal complexes^{22,35}) demonstrates the presence of appropriate bond critical points (BCPs) (3, -1) for intramolecular RAHB O-H...O in **2a-c** (Fig. 5). The low magnitude of the electron density, positive values of the Laplacian, and zero or close to zero positive energy density in these BCPs are typical for hydrogen bonding (Table S3, ESI†). The balance between the Lagrangian kinetic energy $G(r)$ and potential energy density $V(r)$ at these BCPs ($-G(r)/V(r) \geq 1$) reveals the purely non-covalent nature of these interactions. The strength of O-H...O contacts (7.3–11.9 kcal mol⁻¹) corresponds to moderate hydrogen bonds following the classification of Jeffrey ("weak" HBs: <4 kcal mol⁻¹, "moderate" HBs: 15–4 kcal mol⁻¹, "strong" HBs: 40–15 kcal mol⁻¹).³⁶ The negligible values of the Wiberg bond indices for these contacts (0.01–0.04) computed by using the natural bond orbital (NBO) partitioning scheme additionally confirm the electrostatic nature of these non-covalent interactions. The electron-density delocalization in RAHB-involved 7-membered quasi-heterocyclic fragments in **2a-c** has been estimated by the analysis of Wiberg bond indices (WI) for appropriate contacts (Table S4, ESI†). The WI for O-C and C=O contacts in **2a-c** (1.29–1.55) indicate that these bonds are significantly involved in the conjugation. For more detailed information about our DFT calculations see the ESI†.

(iii) The structures of the coupling products. In the molecular structures of **[4b(OTf)(EtOH)](OTf)** and **[4c(OTf)₂]**, the coordination

Fig. 6 Molecular structure of **[4b(OTf)(EtOH)](OTf)** showing the atomic numbering scheme. Thermal ellipsoids are given at the 50% probability level. Fig. 7 Molecular structure of **[4c(OTf)₂]** showing the atomic numbering scheme. Thermal ellipsoids are given at the 50% probability level.

polyhedra of the zinc(II) complexes display a typical distorted octahedral geometry (Fig. 6 and 7). All bond angles around the zinc(II) centers range from 75.44(10) to 119.93(16)°. The Zn-N(1) bond lengths [2.079(4)–2.121(3) Å] exhibit values characteristic for (oxime)Zn^{II} bonds,^{30a} whereas the Zn-N(3) distances [1.944(4)–1.961(3) Å] are usual for (imine)Zn^{II} complexes.^{30a} The Zn-O(2) bond lengths [2.507(4)–2.597(4) Å] are longer than the normal single bonds thus indicating their ionic character,^{30a} the N(2)-C(1) [1.317(7)–1.336(4) Å], N(4)-C(2) [1.330(6)–1.349(6) Å], and N(4)-C(3/4) [1.454(6)–1.466(4) Å] bonds are typical single bonds.²³ The N(1)-C(1) distances and the N(3)-C(2) bond lengths [1.296(4)–1.309(4) Å] indicate an intermediate order between typical single and double bonds,²³ which reflects the amide character of these bonds. The O(1)-N(1) distances [1.438(5)–1.451(3) Å] are longer than usual O-N^{sp2} bonds, which is specific for O-imidoylamidoximes.^{1a} The carbamidoxime groups of both complexes are in the Z-configuration. In the crystal structures of

Fig. 8 Contour line diagram of the Laplacian distribution $\nabla^2\rho(r)$, bond paths and selected zero-flux surfaces for contacts Zn–O and Zn–N in $[4c(OTf)_2]$. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3) in pale brown, and ring critical points (3, +1) in orange, length unit – Å.

$[4b(OTf)(EtOH)](OTf)$ and $[4c(OTf)_2]$, hydrogen bonds between the amide H atoms and the triflate O atoms were observed. The structure of $[4b(OTf)(EtOH)](OTf)$ includes one coordinated EtOH molecule that can be derived from the zinc(II)-mediated cleavage of EtOAc. This additionally confirms the occurrence of the Zn^{II}-mediated hydrolysis of EtOAc giving AcOH and EtOH.

In $[4c(OTf)_2]$, the QTAIM analysis reveals the presence of two BCPs for Zn–O and four BCPs for Zn–N contacts (Fig. 8). The properties of electron density in BCPs for Zn–N contacts are typical for ordinary coordination bonds (the $\rho(r)$ and $\nabla^2\rho(r)$ values are positive and relatively high; the H_b values are significantly negative;

the $-G(r)/V(r) \ll 1$; Wiberg bond indices for these contacts are noticeable), whereas Zn–O contacts can be classified as non-covalent close shell interactions with some contribution of the covalent component (for more detailed information see the ESI†).

(iv) **The structures of the O-iminoacylated oximes.** The structures are similar to those reported previously^{1a,18} and a detailed description of the molecular structures of $[5a](OTf)$ and $[5d](OTf)$ is given in the ESI.†

Zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles

In this work, we succeeded in isolating and identifying zinc(II) complexes featuring amidoximes and aminonitrone and studied the reaction of these (amidoxime/aminonitrone)Zn^{II} complexes with Me_2NCN . All accumulated data combined with those from our previous study¹⁸ on metal-free heterocyclization of amidinium salts $[5]^+$ allowed the formulation of the detailed mechanism of zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles that efficiently proceeds in undried ethyl acetate.

Firstly, complexes **2a–d** are formed *via* coordination of both an amidoxime and AcO^- to the zinc(II) center (Scheme 3, b3 and d3). Acetate is generated *via* the zinc(II)-mediated hydrolysis of EtOAc and this explains why the reaction occurs so easily namely in ethyl acetate (c3). Amidoxime complexes **2a–d** are inactive toward dimethylcyanamide, whereas aminonitrone complexes $[3a–d]^{4+}$ —which are formed from **2a–d** with excess zinc(II) (e3 and f3)—react with Me_2NCN giving imino

species $[4a-c]^{2+}$ (g3 and h3). This observation agrees well with the theoretical calculation data indicating that the nucleophilic addition of amidoximes to electrophilically activated $C\equiv N^{22}$ and $C=C^{37}$ bonds proceeds specifically *via* the aminonitrone form.

Addition of a strong acid (TfOH or *p*-TolSO₃H) leads to the decoordination and liberation of amidinium salts $[5a-d]^+$ (j3). In the case of the $BuC(NH_2)=NOH$ derivative, whose *N*-coordination to the zinc(II) (h3) is sterically hindered, liberation of $[5d]^+$ (j3) occurs even in the absence of an acid. Amidinium salts $[5a-d]^+$ undergo prototropic tautomerization to *O*-iminoacyl amidinium species (k3). For $[RC(NH_2)=NOC(R'')=NH_2]^+$, this step is accelerated by donor *R* and acceptor *R''* substituents. Accordingly, derivatives of conventional nitriles (*R''* = Alk or Ar) are significantly less stable than dialkylcyanamide derivatives (*R''* = NR₂' with strong +*M* effect). Tautomerization (k3) followed by the intramolecular nucleophilic attack of the imine N atom on the electrophilically activated C atom leads to 3-amino-1,2,4-oxadiazoline (l3). The latter compound is subject to aromatization accompanied by the elimination of NH_4^+ giving 1,2,4-oxadiazoles (m3).

Concluding remarks

In this work, we succeeded in generating, isolating, and fully characterizing the trinuclear zinc(II) species $[3a-d](OTf)_4$, which most likely serve as key intermediates in the Zn^{II}-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles in EtOAc.^{1a,18} The amidoxime ligands in $[3a-d](OTf)_4$ are stabilized in their aminonitrone form, $RC(NH_2)=N^+(H)O^-$, and they act as μ_2 -ligands being coordinated through the O atom. Before our experiments, this type of coordination was unknown for amidoxime zinc(II) complexes and this ligation pattern was observed only at a molybdenum(VI) center.^{19,28}

All accumulated reactivity data, combined with those from our previous study¹⁸ on metal-free heterocyclization of amidinium salts $[5]^+$, allowed the formulation of the detailed mechanism of the zinc(II)-mediated generation of 1,2,4-oxadiazoles from amidoximes and nitriles and the explanation of the effect of undried ethyl acetate on facilitation of the heterocyclization (Scheme 3). It is now clear that the overall reaction consists of four main steps namely the acetate-promoted formation of the trinuclear complexes, amidoxime–nitrile coupling, acid driven decoordination, and, eventually, the heterocyclization. All these data allowed the rational choice of the reactants and further tuning of the reaction conditions. It is noteworthy that although for a while we are satisfied with improving the synthesis of 1,2,4-oxadiazoles with stoichiometric amounts of zinc(II), our distant goal is to find out a catalytic system for the preparation of 1,2,4-oxadiazoles and we are currently testing appropriate catalytic systems.

One more issue requires additional attention. Zinc(II) centers belong to the category of kinetically labile metal centers when ambidentate or, in general, ligands with multiple donor centers are subject to facile linkage isomerization giving various coordination pattern species. In this respect, the different reactivity of **2a-d**

and $[3a-d](OTf)_4$ toward the coupling with Me₂NCN is surprising. The observed high reactivity of the trinuclear complexes can be further explored in at least two directions: (i) nitrones, as allyl anion type dipoles, are involved in cycloaddition reactions with various dipolarophiles.³⁸ Although amidoximes exist in tautomeric equilibrium with their aminonitrone form $RC(NH_2)=N^+(H)O^-$, aminonitrone reactivity (*e.g.* toward cycloaddition) has never been observed in the past. The obtained aminonitrone trinuclear complexes represent available reactants for the inverse electron demand cycloaddition (type III in Sustman's classification³⁹), when the reaction involves complexed dipole and uncoordinated dipolarophile; (ii) many organic reactions involving polynuclear metal species proceed *via* simultaneous coordination of two reactants to the adjacent metal centers, which, *via* the so-called “two-metal-mechanism”,⁴⁰ couples intramolecularly. One can assume that substrates with donor centers could split the $[Zn^{II}]_2\{\mu_2-ON(H)=C(NR_2)R'\}$ bridge by their ligation to a zinc(II) center followed by intramolecular coupling with aminonitrones leading to novel organic species. All works in these two directions are underway in our group.

Experimental section

Materials and instrumentation

Solvents were obtained from commercial sources and used as received. All of the syntheses were conducted in an air atmosphere. Amidoximes **1a-d** were synthesized according to the literature methods.^{1a} Melting points were measured on a Stuart SMP30 apparatus in capillaries and were not corrected. Microanalyses (C, H, N) were carried out on a Euro EA3028-HT instrument. Electrospray ionization mass-spectra were obtained on a Bruker micrOTOF spectrometer equipped with an electrospray ionization (ESI) source. The instrument was operated both in negative and positive ion modes in the *m/z* range 50–3000. The nebulizer gas flow was 0.4 bar and the drying gas flow was 4.0 L min^{−1}. For HRESI, complexes were dissolved in MeOH. In the isotopic pattern, the most intensive peak is reported. Infrared spectra (4000–400 cm^{−1}) were recorded on a Shimadzu IR Prestige-21 instrument in KBr pellets. ¹H and ¹³C{¹H} NMR spectra were measured on a Bruker Avance 400 at ambient temperature; residual solvent signals were used as the internal standard. Solid state CP-MAS TOSS ¹³C{¹H} NMR spectra were measured on Bruker Avance III WB 400 with the magic angle spinning at 6 kHz frequency.

X-ray structure determination

The single-crystal X-ray diffraction experiment was carried out using Agilent Technologies “Xcalibur” and “Supernova” diffractometers with monochromated MoK α or CuK α radiation, respectively. The crystal was fixed on a micro mount, placed on the diffractometer and measured at a temperature of 100 K. The unit cell parameters and other summarized data are represented in Tables 1S and 2S (ESI†). The structure has been solved by using the Superflip⁴¹ structure solution program using charge flipping and refined using the ShelXL⁴² refinement

incorporated in the OLEX2 program package.⁴³ The hydrogen atoms were placed in calculated positions and were included in the refinement in the 'riding' model approximation. Empirical absorption correction was applied in the CrysAlisPro⁴⁴ program complex using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm. CCDC 1503999–1504006.

Computational details

The single point calculations based on the experimental X-ray geometries (quasi-solid-state approach) have been carried out at the DFT level of theory using the M06-2X functional³⁴ (this functional was specifically developed to describe weak dispersion forces and non-covalent interactions) with the help of Gaussian-09⁴⁵ program package. The standard 6-311+G(d,p) basis sets have been used for all atoms. The topological analysis of the electron density distribution with the help of the atoms-in-molecules (QTAIM) method developed by Bader³⁴ has been performed by using the Multiwfn program (version 3.3.7).⁴⁶ The Wiberg bond indices (WI) were computed by using the natural bond orbital (NBO) partitioning scheme.⁴⁷ The Cartesian atomic coordinates of model structures are presented in ESI,† Table S5.

Syntheses and characterization

Preparation of 2a–d. Powders of **1a–d** (1 mmol) were added to a solution of Zn(OAc)₂·2H₂O (109.8 mg; 0.5 mmol) in acetone (6 mL) placed in a 10 mL round-bottomed flask. The solution was stirred for 5 min at 50 °C, and then evaporated *in vacuo* at 50 °C. An oily residue was crystallized under chloroform (1.5 mL) with ultrasound treatment. The resulting precipitate was filtered off, and dried in air at 50 °C.

2a. Yield: 80% (182.3 mg). Mp: 145 °C (dec.). Anal. calcd for C₁₈H₂₂N₄O₆Zn: C, 47.43; H, 4.87; N, 12.29. Found: C, 47.88; H, 4.75; N, 12.28. HRESI⁺-MS (MeOH, *m/z*): 259.0059 ([M-PhC(NH₂)=NOH-OAc]⁺, calcd 259.0056), 335.0469 ([M-2OAc-H]⁺, calcd 335.0481), 382.9346 ([M + Zn-PhC(NH₂)=NOH-H]⁺, calcd 382.9372), 458.9771 ([M + Zn-OAc-2H]⁺, calcd 458.9798), 518.9991 ([M + Zn-H]⁺, calcd 519.0001), 579.0156 ([M + Zn + OAc]⁺, calcd 579.0222). HRESI⁻-MS (*m/z*): 240.9730 ([Zn(OAc)₃]⁻, calcd 240.9685), 424.9288 ([Zn₂(OAc)₅]⁻, calcd 424.9213). IR (KBr, selected bands, cm⁻¹): 3464(s), 3318(s), 3178(m) ν(N-H); 3060 (m), 2876(w-m) ν(C-H); 1662(vs) ν(C=N); 1564(vs), 1420(vs), 1340(s) ν(C=O). ¹H NMR ((CD₃)₂CO, δ): 7.64 (d, br, 2H, *o*-CH), 7.46–7.38 (m, 3H, *p*-CH and *m*-CH), 5.92 (s, br, 2H, NH₂), 1.91 (s, 3H, CH₃). CP-MAS TOSS ¹³C{¹H} NMR (δ): 180.23, 178.18 (CH₃CO₂); 158.59 (C=N); 132.73, 130.56, 128.23, 126.98, 126.15 (Ar); 24.03, 22.03 (CH₃). Crystals

of **2a** suitable for X-ray diffraction were obtained by slow evaporation of Me₂CO solution at RT in air.

2b. Yield: 82% (215.1 mg). Mp: 177 °C (dec.). Anal. calcd for C₁₈H₂₀N₄Cl₂O₆Zn: C, 41.21; H, 3.84; N, 10.68. Found: C, 40.95; H, 3.61; N, 10.81. HRESI⁺-MS (MeOH, *m/z*): 292.9671 ([M-ClC₆H₄C(NH₂)=NOH-OAc]⁺, calcd 292.9666), 404.9651 ([M-2OAc-H]⁺, calcd 404.9672), 528.8963 ([M + Zn-OAc-2H]⁺, calcd 528.8997), 588.9170 ([M + Zn-H]⁺, calcd 588.9209), 648.9371 ([M + Zn + OAc]⁺, calcd 648.9421). HRESI⁻-MS (*m/z*): 240.9745 ([Zn(OAc)₃]⁻, calcd 240.9685), 424.9309 ([Zn₂(OAc)₅]⁻, calcd 424.9213). IR (KBr, selected bands, cm⁻¹): 3498(s), 3406(s), 3362(s), 3202(m-s) ν(N-H); 3078(m-s), 2832(s) ν(C-H); 1662(vs) ν(C=N); 1574(vs), 1402(vs), 1340(s) ν(C=O). ¹H NMR ((CD₃)₂CO, δ): 7.50–7.43 (m, 3H, CH), 7.40–7.36 (m, 1H, CH), 6.27 (s, br, 2H, NH₂), 1.78 (s, 3H, CH₃). CP-MAS TOSS ¹³C NMR (δ): 176.94, 175.69 (CH₃CO₂); 155.53, 153.57 (C=N); 135.27, 132.56, 130.67, 127.51, 126.48 (Ar); 22.94, 20.36 (CH₃). Crystals of **2b** suitable for X-ray diffraction were obtained by slow evaporation of Me₂CO solution at RT in air.

2c. Yield: 75% (134.9 mg). Mp: 158 °C (dec.). Anal. calcd for C₁₀H₂₂N₄O₆Zn: C, 33.39; H, 6.16; N, 15.58. Found: C, 33.20; H, 6.07; N, 15.37. HRESI⁺-MS (MeOH, *m/z*): 239.0464 ([M-2OAc-H]⁺, calcd 239.0481), 334.9346 ([M + Zn-EtC(NH₂)=NOH-H]⁺, calcd 334.9372), 362.9748 ([M + Zn-OAc-2H]⁺, calcd 362.9797), 422.9979 ([M + Zn-H]⁺, calcd 423.0009), 483.0190 ([M + Zn + OAc]⁺, calcd 483.0221). HRESI⁻-MS (*m/z*): 240.9729 ([Zn(OAc)₃]⁻, calcd 240.9685), 424.9282 ([Zn₂(OAc)₅]⁻, calcd 424.9213). IR (KBr, selected bands, cm⁻¹): 3484(s), 3428(s), 3344(s-vs), 3218(s) ν(N-H); 3088(m), 2990(s), 2880(m-s), 2772(m) ν(C-H); 1672(vs) ν(C=N); 1562(vs), 1412(vs), 1346(vs) ν(C=O). ¹H NMR ((CD₃)₂CO, δ): 6.40 (s, br, 2H, NH₂), 2.30 (q, 2H, CH₂), 1.92 (s, 3H, CH₃), 1.16 (t, 3H, CH₃). CP-MAS TOSS ¹³C{¹H} NMR (δ): 182.47, 178.12 (CH₃CO₂); 160.93 (C=N);

25.41 (CH_2CH_3); 22.98, 21.56 (CH_3CO_2); 12.85, 11.43 (CH_2CH_3). Crystals of **2c** suitable for X-ray diffraction were obtained by slow evaporation of Me_2CO solution at RT in air.

2d. Yield: 78% (162.2 mg). Mp: 98 °C (dec.). Anal. calcd for $\text{C}_{14}\text{H}_{30}\text{N}_4\text{O}_6\text{Zn}$: C, 40.44; H, 7.27; N, 13.47. Found: C, 40.54; H, 7.19; N, 13.69. HRESI⁺-MS (MeOH, m/z): 239.0439 ($[\text{M}-\text{tBu}(\text{NH}_2)=\text{NOH}-\text{OAc}]^+$, calcd 239.0369), 295.1099 ($[\text{M}-2\text{OAc}-\text{H}]^+$, calcd 295.1107), 419.0406 ($[\text{M} + \text{Zn}-\text{OAc}-2\text{H}]^+$, calcd 419.0423), 479.0717 ($[\text{M} + \text{Zn}-\text{H}]^+$, calcd 479.0831), 539.0819 ($[\text{M} + \text{Zn} + \text{OAc}]^+$, calcd 539.0847). HRESI⁻-MS (m/z): 240.9727 ($[\text{Zn}(\text{OAc})_3]^-$, calcd 240.9685), 424.9351 ($[\text{Zn}_2(\text{OAc})_5]^-$, calcd 424.9213). IR (KBr, selected bands, cm^{-1}): 3434(s), 3302(s), 3164(m-s) $\nu(\text{N}-\text{H})$; 2976(s) $\nu(\text{C}-\text{H})$; 1668(vs) $\nu(\text{C}=\text{N})$; 1608(vs), 1498(s), 1396(vs) $\nu(\text{C}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{CO}$, δ): 5.29 (s, br, 2H, NH_2), 1.97 (s, 3H, CH_3), 1.19 (s, 9H, CH_3). CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ NMR (δ): 176.91; 176.40 (CH_3CO_2); 160.93 ($\text{C}=\text{N}$); 33.87, 33.50 ($\text{C}(\text{CH}_3)_3$); 27.27, 27.00 ($\text{C}(\text{CH}_3)_3$); 23.47, 22.89 (CH_3CO_2).

Preparation of [3a-d](OTf)₄. Route b2. Powders of **1a-d** (1 mmol) were added to a stirred solution of the corresponding complexes **2a-d** (0.5 mmol) and $\text{Zn}(\text{OTf})_2$ (363.52 mg; 1 mmol) in acetone (6 mL) placed in a 10 mL round-bottomed flask. The solution was stirred for 5 min at 50 °C, whereupon the solvent was evaporated *in vacuo* at 50 °C. Route c2. Powders of **1a-d** (2 mmol) were added to a stirred solution of $\text{Zn}(\text{OTf})_2$ (545.3 mg; 1.5 mmol) in ethyl acetate (10 mL) placed in a 25 mL round-bottomed flask. The solution was stirred for 30 min on reflux, and then the solvent was evaporated *in vacuo* at 50 °C. For both routes, the oily residue that was formed was crystallized under chloroform (1.5 mL) with ultrasound treatment. The resulting precipitate was filtered off, and dried at 50 °C (route b2) or at 70 °C (route c) in air. The yields are given for route c. For route b2, the yields are 80–90% based on the corresponding **2a-d**.

[3a](OTf)₄. Yield: 87% (680 mg). Mp: 116 °C (dec.). Anal. calcd for $\text{C}_{36}\text{H}_{50}\text{N}_8\text{F}_{12}\text{O}_{26}\text{S}_4\text{Zn}_3$: C, 27.66; H, 3.22; N, 7.17. Found: C, 27.44; H, 2.99; N, 7.21. HRESI⁺-MS (MeOH, m/z): 259.0067 ($[\text{Zn}(\text{OAc})(\text{PhC}(\text{NH}_2)=\text{NOH})]^+$, calcd 259.0056), 335.0433 ($[\text{Zn}(\text{PhC}(\text{NH}_2)=\text{NOH})-\text{H}]^+$, calcd 335.0481), 382.9308 ($[\text{Zn}_2(\text{OAc})_2(\text{PhC}(\text{NH}_2)=\text{NOH})-\text{H}]^+$, calcd 382.9372), 458.9737 ($[\text{Zn}_2(\text{OAc})(\text{PhC}(\text{NH}_2)=\text{NOH})_2-2\text{H}]^+$, calcd 458.9798), 518.9933 ($[\text{Zn}_2(\text{OAc})_2(\text{PhC}(\text{NH}_2)=\text{NOH})_2-\text{H}]^+$, calcd 519.0001), 579.0156 ($[\text{Zn}_2(\text{OAc})_3(\text{PhC}(\text{NH}_2)=\text{NOH})_2]^+$, calcd 579.0222). HRESI⁻-MS (m/z): 646.8494 ($[\text{Zn}(\text{OTf})_3(\text{PhC}(\text{NH}_2)=\text{NOH})]^-$, calcd 646.8483), 862.7197 ($[\text{Zn}_2(\text{OTf})_4(\text{PhC}(\text{NH}_2)=\text{NOH})-\text{H}]^-$, calcd 862.7167). IR (KBr, selected bands, cm^{-1}): 3412(s), 3216(s) $\nu(\text{O}-\text{H})$ and $\nu(\text{N}-\text{H})$; 2968(w), 2868(w) $\nu(\text{C}-\text{H})$; 1658(vs) $\nu(\text{C}=\text{N})$; 1570(vs), 1448(s),

1404(s) $\nu(\text{C}=\text{O})$; 1246(vs), 1174(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{CO}$, δ): 8.48 (s, br, 2H, NH_2), 7.83 (m, br, 2H, *o*-CH), 7.73 (t, br, 1H, *p*-CH), 7.62 (t, br, 2H, *m*-CH), 1.95 (s, 3H, CH_3). CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ NMR (δ): 178.42 (CH_3CO_2); 157.59 ($\text{C}=\text{N}$); 133.77, 133.09, 131.54, 127.15, 124.37 (Ar); 119.12 (CF_3); 26.10 (CH_3). Crystals of **[3a](OTf)₄** suitable for X-ray diffraction were obtained by slow evaporation of Me_2CO solution at RT in air.

[3b](OTf)₄. Yield: 73% (620.9 mg). Mp: 119 °C (dec.). Anal. calcd for $\text{C}_{36}\text{H}_{46}\text{N}_8\text{Cl}_4\text{F}_{12}\text{O}_{26}\text{S}_4\text{Zn}_3$: C, 25.42; H, 2.73; N, 6.59. Found: C, 25.60; H, 2.51; N, 6.84. HRESI⁺-MS (MeOH, m/z): 292.9639 ($[\text{Zn}(\text{OAc})(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})]^+$, calcd 292.9666), 404.9625 ($[\text{Zn}(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})_2-\text{H}]^+$, calcd 404.9672), 416.8932 ($[\text{Zn}_2(\text{OAc})_2(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})-\text{H}]^+$, calcd 416.8982), 528.8937 ($[\text{Zn}_2(\text{OAc})(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})_2-2\text{H}]^+$, calcd 528.8997), 588.9144 ($[\text{Zn}_2(\text{OAc})_2(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})_2-\text{H}]^+$, calcd 588.9209), 648.9352 ($[\text{Zn}_2(\text{OAc})_3(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})_2]^+$, calcd 648.9421). HRESI⁻-MS (m/z): 682.7972 ($[\text{Zn}(\text{OTf})_3(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})]^-$, calcd 682.8064), 896.6801 ($[\text{Zn}_2(\text{OTf})_4(\text{ClC}_6\text{H}_4\text{C}(\text{NH}_2)=\text{NOH})-\text{H}]^-$, calcd 896.6775). IR (KBr, selected bands, cm^{-1}): 3422(s), 3314(w-m), 3234(s) $\nu(\text{O}-\text{H})$ and $\nu(\text{N}-\text{H})$; 2994(sh), 2898(w) $\nu(\text{C}-\text{H})$; 1670(s) $\nu(\text{C}=\text{N})$; 1574(vs), 1438(s), 1406(s), 1350(m) $\nu(\text{C}=\text{O})$; 1250(vs), 1174(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{CO}$, δ): 7.93 (s, br, 2H, NH_2), 7.68 (m, 1H, CH), 7.62 (m, 1H, CH), 7.52 (m, 2H, CH), 1.95 (s, 3H, CH_3). CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ NMR (δ): 177.82 (CH_3CO_2); 152.40 ($\text{C}=\text{N}$); 130.61, 128.63, 124.60 (Ar); 119.31, 116.28 (CF_3); 23.48, 22.31, 21.36 (CH_3).

[3c](OTf)₄. Yield: 73% (500.4 mg). Mp: 106 °C (dec.). Anal. calcd for $\text{C}_{20}\text{H}_{50}\text{N}_8\text{F}_{12}\text{O}_{26}\text{S}_4\text{Zn}_3$: C, 17.52; H, 3.68; N, 8.17. Found: C, 17.77; H, 3.46; N, 8.43. HRESI⁺-MS (MeOH, m/z): 211.0127 ($[\text{Zn}(\text{OAc})(\text{EtC}(\text{NH}_2)=\text{NOH})]^+$, calcd 211.0056), 239.0471 ($[\text{Zn}(\text{EtC}(\text{NH}_2)=\text{NOH})_2-\text{H}]^+$, calcd 239.0481), 334.9362 ($[\text{Zn}_2(\text{OAc})_2(\text{EtC}(\text{NH}_2)=\text{NOH})-\text{H}]^+$, calcd 334.9372), 362.9773 ($[\text{Zn}_2(\text{OAc})(\text{EtC}(\text{NH}_2)=\text{NOH})_2-2\text{H}]^+$, calcd 362.9797), 422.9981 ($[\text{Zn}_2(\text{OAc})_2(\text{EtC}(\text{NH}_2)=\text{NOH})_2-\text{H}]^+$, calcd 423.0009),

483.0202 ($[\text{Zn}_2(\text{OAc})_3(\text{EtC}(\text{NH}_2)=\text{NOH})_2]^+$, calcd 483.0221). HRESI⁺-MS (m/z): 598.8526 ($[\text{Zn}(\text{OTf})_3(\text{EtC}(\text{NH}_2)=\text{NOH})]^-$, calcd 598.8483). IR (KBr, selected bands, cm^{-1}): 3454(s), 3364(s), 3232(s), 3126(m) $\nu(\text{O}-\text{H})$ and $\nu(\text{N}-\text{H})$; 2994(m), 2894(w-m) $\nu(\text{C}-\text{H})$; 1676(vs) $\nu(\text{C}=\text{N})$; 1572(vs), 1444(s), 1404(s) $\nu(\text{C}=\text{O})$; 1252(vs), 1170(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{CO}$, δ): 8.44 (s, br, 2H, NH_2), 2.68, 2.66 (q, 2H, CH_2), 2.02 (s, 3H, CH_3), 1.35 (t, 3H, CH_3). CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ NMR (δ): 177.12 (CH_3CO_2); 159.71 ($\text{C}=\text{N}$), 117.79 (CF_3); 24.93, 20.12 (CH_2 and CH_3CO_2); 6.70, 5.89, 5.14 (CH_2CH_3).

[3d](OTf)₄. Yield: 70% (519.1 mg). Mp: 73 °C (dec.). Anal. calcd for $\text{C}_{28}\text{H}_{66}\text{N}_8\text{F}_{12}\text{O}_{26}\text{S}_4\text{Zn}_3$: C, 22.67; H, 4.48; N, 7.55. Found: C, 22.44; H, 4.26; N, 7.81. HRESI⁺-MS (MeOH, m/z): 239.0481 ($[\text{Zn}(\text{OAc})(^t\text{BuC}(\text{NH}_2)=\text{NOH})]^+$, calcd 239.0369), 295.1095 ($[\text{Zn}(^t\text{BuC}(\text{NH}_2)=\text{NOH})_2\text{-H}]^+$, calcd 295.1107), 419.0386 ($[\text{Zn}_2(\text{OAc})(^t\text{BuC}(\text{NH}_2)=\text{NOH})_2\text{-2H}]^+$, calcd 419.0423), 479.0626 ($[\text{Zn}_2(\text{OAc})_2(^t\text{BuC}(\text{NH}_2)=\text{NOH})_2\text{-H}]^+$, calcd 479.0635), 539.0819 ($[\text{Zn}_2(\text{OAc})_3(^t\text{BuC}(\text{NH}_2)=\text{NOH})_3]^+$, calcd 539.0847). HRESI⁻-MS (m/z): 626.8803 ($[\text{Zn}(\text{OTf})_3(^t\text{BuC}(\text{NH}_2)=\text{NOH})]^-$, calcd 626.8796), 840.7540 ($[\text{Zn}_2(\text{OTf})_4(^t\text{BuC}(\text{NH}_2)=\text{NOH})\text{-H}]^-$, calcd 840.7499). IR (KBr, selected bands, cm^{-1}): 3446(vs), 3314(vs), 3238(vs) $\nu(\text{O}-\text{H})$ and $\nu(\text{N}-\text{H})$; 2980(s), 2884(m) $\nu(\text{C}-\text{H})$; 1668(vs) $\nu(\text{C}=\text{N})$; 1564(s-vs), 1440(s), 1376(s) $\nu(\text{C}=\text{O})$; 1250(vs), 1178(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{CO}$, δ): 8.37 (s, br, 2H, NH_2), 2.01 (s, 3H, CH_3), 1.45 (s, 9H, CH_3). CP-MAS TOSS $^{13}\text{C}\{^1\text{H}\}$ NMR (δ): 179.94 (CH_3CO_2); 164.47 ($\text{C}=\text{N}$); 120.62, 118.24 (CF_3); 34.45, 33.30 ($\text{C}(\text{CH}_3)_3$); 26.38, 25.77, 25.57, 23.30 (CH_3CO_2 and $\text{C}(\text{CH}_3)_3$).

Preparation of [4a-c(OTf)₂] and [5d](OTf). Me_2NCN (161.0 μL ; 2 mmol) was added to a stirred solution of [3a-c](OTf)₄ (0.5 mmol) in EtOAc (10 mL) (Scheme 2, route d2) or to a stirred solution of 1a-c (2 mmol) and $\text{Zn}(\text{OTf})_2$ (363.5 mg; 1 mmol) in EtOAc (10 mL) (route e2). The solution was kept for 3 h at RT and then the resulting precipitate was filtered off, washed by three 1 mL portions of EtOAc, and dried at 50 °C. The yields are given for route e2. For route d2, the yields are 93–98% based on the corresponding [3a-c](OTf)₄. In the case of 1d (route e2) or [3d](OTf)₄ (route d2), the reaction results in the precipitation of [5d](OTf) in 79% (route e2) or 98% (route d2) yields.

[4a(OTf)₂]. Yield: 76% (589.8 mg). Mp: 150 °C (dec.). Anal. calcd for $\text{C}_{22}\text{H}_{28}\text{N}_8\text{F}_6\text{O}_8\text{S}_2\text{Zn}$: C, 34.05; H, 3.64; N, 14.44. Found: C, 34.31; H, 3.86; N, 14.58. HRESI⁺-MS (MeOH, m/z): 419.0003 ($[\text{M}-\text{PhC}(\text{NH}_2)=\text{NOC}(\text{NMe}_2)=\text{NH}-\text{OTf}]^+$, calcd 418.9974), 625.1183 ($[\text{M}-\text{OTf}]^+$, calcd 625.1141). HRESI⁻-MS (m/z): 505.0375 ($[\text{PhC}(\text{NH}_2)=\text{NOC}(\text{N}(\text{CH}_3)_2)=\text{NH}_2+2\text{OTf}]^-$, calcd 505.0281). IR (KBr, selected bands, cm^{-1}): 3344(m-s), 3202(m-s) $\nu(\text{N}-\text{H})$; 3074(w), 2948(w-m), 2826(w) $\nu(\text{C}-\text{H})$; 1642(vs) $\nu(\text{C}=\text{N})$; 1286(vs), 1246(vs), 1168(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{SO}$, δ): 7.95 (s, br, 1H, NH_2), 7.64–7.61 (m, br, 3H, *o*-CH and NH_2), 7.54–7.47 (m, br, 4H, *p*-CH, *m*-CH and NH_2), 5.18 (s, 1H, NH), 2.83 (s, br, 6H, NMe_2). $^{13}\text{C}\{^1\text{H}\}$ NMR ($(\text{CD}_3)_2\text{SO}$, δ): 160.30, 159.28 ($\text{PhC}(\text{N})=\text{NH}_2$ and $\text{OC}(\text{N})\text{NMe}_2$); 131.85, 130.67, 128.91, 128.76 (Ph); 121.16 (q, CF_3); 37.44 (CH_3).

[4b(OTf)₂]. Yield: 80% (675.9 mg). Mp: 127 °C (dec.). Anal. calcd for $\text{C}_{22}\text{H}_{26}\text{N}_8\text{Cl}_2\text{F}_6\text{O}_8\text{S}_2\text{Zn}$: C, 31.27; H, 3.10; N, 13.26. Found: C, 31.17; H, 2.91; N, 13.26. HRESI⁺-MS (MeOH, m/z): 695.0393 ($[\text{M}-\text{OTf}]^+$, calcd 695.0334). HRESI⁻-MS (m/z): 539.0013 ($[\text{o-ClC}_6\text{H}_4\text{ClC}(\text{NH}_2)=\text{NOC}(\text{N}(\text{CH}_3)_2)=\text{NH}_2+2\text{OTf}]^-$, calcd 538.9891). IR (KBr, selected bands, cm^{-1}): 3350(s), 3206(m-s) $\nu(\text{N}-\text{H})$; 2944(w-m) $\nu(\text{C}-\text{H})$; 1638(vs) $\nu(\text{C}=\text{N})$; 1280(vs), 1248(vs), 1160(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{SO}$, δ): 7.98 (s, br, 1H, NH_2), 7.60 (m, br, 2H, CH and NH_2), 7.47 (m, br, 4H, CH and NH_2), 4.78 (s, 1H, NH), 2.80 (s, br, 3H, NMe), 2.64 (s, br, 3H, NMe). $^{13}\text{C}\{^1\text{H}\}$ NMR ($(\text{CD}_3)_2\text{SO}$, δ): 159.52, 155.68 ($\text{o-ClC}_6\text{H}_4\text{C}(\text{N})\text{NH}_2$ and $\text{OC}(\text{N})\text{NMe}_2$); 132.72, 132.38, 131.52, 130.33, 129.89, 127.36 (Ar); 121.16 (q, CF_3); 37.32 (CH_3). Crystals of [4b(OTf)(EtOH)](OTf) suitable for X-ray diffraction were obtained by slow evaporation of undried EtOAc solution of the complex at RT in air.

[4c(OTf)₂]. Yield: 82% (557.5 mg). Mp: 156 °C (dec.). Anal. calcd for $\text{C}_{14}\text{H}_{28}\text{N}_8\text{F}_6\text{O}_8\text{S}_2\text{Zn}$: C, 24.73; H, 4.15; N, 16.48. Found: C, 24.85; H, 4.28; N, 16.74. HRESI⁺-MS (MeOH, m/z): 370.9999 ($[\text{M}-\text{EtC}(\text{NH}_2)=\text{NOC}(\text{NMe}_2)=\text{NH}-\text{OTf}]^+$, calcd 370.9974), 529.1189 ($[\text{M}-\text{OTf}]^+$, calcd 529.1141). HRESI⁻-MS (m/z): 457.0401 ($[\text{EtC}(\text{NH}_2)=\text{NOC}(\text{N}(\text{CH}_3)_2)=\text{NH}_2+\text{OTf}]^-$, calcd 457.0290). IR (KBr, selected bands, cm^{-1}): 3460(m-s), 3374(s), 3224(m) $\nu(\text{N}-\text{H})$; 2982(m), 2946(m), 2890(w-m) $\nu(\text{C}-\text{H})$; 1642(vs) $\nu(\text{C}=\text{N})$; 1290(vs), 1244(vs), 1162(vs) $\nu(\text{S}=\text{O})$. ^1H NMR ($(\text{CD}_3)_2\text{SO}$, δ): 7.57 (s, br, 1H, NH_2), 7.12 (s, br, 1H, NH_2), 6.21 (s, 1H, NH), 3.02 (s, br, 6H, NMe_2), 2.20 (q, 2H, CH_2), 1.19 (t, 3H, CH_3). $^{13}\text{C}\{^1\text{H}\}$ NMR ($(\text{CD}_3)_2\text{SO}$, δ): 161.23, 160.85

(CH₂C(=N)NH₂ and OC(=N)NMe₂); 121.15 (q, CF₃); 37.61 (NMe₂); 24.61 (CH₂); 12.13 (CH₂CH₃). Crystals of [4c(OTf)]₂ suitable for X-ray diffraction were obtained by slow evaporation of wet EtOAc solution of the complex at RT in air.

[5d](OTf). Yield: 79% (531.4 mg). Mp: 120 °C (dec.). Anal. calcd for C₉H₁₉N₄F₃O₄S: C, 32.14; H, 5.69; N, 16.66. Found: C, 32.01; H, 5.47; N, 16.65. HRESI⁺-MS (MeOH, *m/z*): 187.1584 ([M]⁺, calcd 187.1553), 523.2684 ([2M + OTf]⁺, calcd 523.2632). HRESI[−]-MS (*m/z*): 485.0734 ([M + 2OTf][−], calcd 485.0594). IR (KBr, selected bands, cm^{−1}): 3422(vs), 3360(vs), 3290(s-vs), 3242(s-vs) ν(N-H); 2982(m-s), 2882(m) ν(C-H); 1694(vs) ν(C=N)_{oxime}; 1652(vs) ν(C=N)_{imine}; 1264(vs), 1162(vs) ν(S=O). ¹H NMR ((CD₃)₂SO, δ): 8.51 (s, br, 1H, NH₂), 7.92 (s, br, 1H, NH₂), 6.63 (s, 2H, NH₂), 3.05 (s, 6H, NMe₂), 1.20 (s, 9H, CH₃). CP-MAS TOSS ¹³C{¹H} NMR (δ): 162.95, 156.86 (CC(=N)NH₂ and OC(=N)NMe₂); 116.01 (CF₃); 35.20 (NMe₂); 32.96 (CMe₃); 24.28 (Me). Crystals of [5d](OTf) suitable for X-ray diffraction were obtained by slow evaporation of Me₂CO solution at RT in air.

Preparation of [5a-c](OTf). A solution of trifluoromethane-sulfonic acid (88.3 μL; 1 mmol) in methanol (1 mL) was dropwise added to a stirred solution of [4a-c](OTf)₂ (0.5 mmol) in methanol (1 mL) placed in a 5 mL round-bottomed flask. The solution was kept for 5 min at RT and then the solvent was evaporated *in vacuo* at RT. The oily residue was crystallized under ethyl acetate and dried at RT in air.

[5a](OTf). Yield: 87% (310.0 mg). Mp: 129 °C (dec.). Anal. calcd for C₁₁H₁₅N₄F₃O₄S: C, 37.08; H, 4.24; N, 15.72. Found: C, 37.12; H, 4.05; N, 15.68. HRESI⁺-MS (MeOH, *m/z*): 207.1240 ([M]⁺, calcd 207.1240), 563.1990 ([2M + OTf]⁺, calcd 563.2006). HRESI[−]-MS (*m/z*): 505.0292 ([M + 2OTf][−], calcd 505.0281). IR (KBr, selected bands, cm^{−1}): 3442(m-s), 3350(s), 3242(m) ν(N-H); 2958(m), 2896(m) ν(C-H); 1688(vs) ν(C=N)_{oxime}; 1654(vs) ν(C=N)_{imine}; 1258(vs), 1168(vs) ν(S=O). ¹H NMR ((CD₃)₂SO, δ): 8.68 (s, br, 2H, NH₂), 7.87–7.85 (m, 2H, *o*-CH), 7.60–7.56 (m, 1H, *p*-CH), 7.53–7.49 (m, 2H, *m*-CH) 7.34 (s, br,

2H, NH₂), 3.14 (s, br, 6H, NMe₂). ¹³C{¹H} NMR ((CD₃)₂SO, δ): 159.96, 158.16 (PhC(=N)NH₂ and OC(=N)NMe₂); 131.73, 130.50, 128.93, 127.86 (Ph); 121.17 (q, CF₃); 38.35, 37.27 (CH₃). Crystals of [5a](OTf) suitable for X-ray diffraction were obtained by slow evaporation of Me₂CO solution at RT in air.

[5b](OTf). Yield: 92% (359.5 mg). Mp: 75 °C (dec.). Anal. calcd for C₁₁H₁₄N₄ClF₃O₄S: C, 33.81; H, 3.61; N, 14.34. Found: C, 33.83; H, 3.75; N, 14.29. HRESI⁺-MS (MeOH, *m/z*): 241.0835 ([M]⁺, calcd 241.0851), 631.1207 ([2M + OTf]⁺, calcd 631.1227). HRESI[−]-MS (*m/z*): 538.9957 ([M + 2OTf][−], calcd 538.9891). IR (KBr, selected bands, cm^{−1}): 3442(s), 3348(s), 3290(s), 3238(s) ν(N-H); 2956(w), 2858(w) ν(C-H); 1686(vs) ν(C=N)_{oxime}; 1650(vs) ν(C=N)_{imine}; 1254(vs), 1172(vs) ν(S=O). ¹H NMR ((CD₃)₂SO, δ): 8.74 (s, br, 1H, NH₂), 8.48 (s, br, 1H, NH₂), 7.62–7.54 (m, 5H, *m*-, *p*-CH and NH₂), 7.49–7.45 (m, 2H, *o*-CH and NH₂), 3.12 (s, br, 6H, NMe₂). ¹³C{¹H} NMR ((CD₃)₂SO, δ): 159.75, 157.34 (ClC₆H₄C(=N)NH₂ and OC(=N)NMe₂); 132.82, 132.43, 131.86, 130.68, 130.17, 127.66 (Ar); 121.16 (q, CF₃); 38.29, 37.28 (CH₃).

[5c](OTf). Yield: 90% (277.5 mg). Mp: 103 °C (dec.). Anal. calcd for C₇H₁₅N₄F₃O₄S: C, 27.27; H, 4.90; N, 18.17. Found: C, 27.42; H, 4.79; N, 18.18. HRESI⁺-MS (MeOH, *m/z*): 159.1231 ([M]⁺, calcd 159.1240), 467.1990 ([2M + OTf]⁺, calcd 467.2006). HRESI[−]-MS (*m/z*): 457.0290 ([M + 2OTf][−], calcd 457.0280). IR (KBr, selected bands, cm^{−1}): 3426(s), 3358(s), 3246(s) ν(N-H); 2988(m), 2952(m), 2892(m) ν(C-H); 1690(vs) ν(C=N)_{oxime}; 1666(vs) ν(C=N)_{imine}; 1274(vs), 1160(vs) ν(S=O). ¹H NMR ((CD₃)₂SO, δ): 8.63 (s, br, 1H, NH₂), 8.37 (s, br, 1H, NH₂), 6.97 (s, br, 1H, NH), 6.78 (s, br, 1H, NH), 3.06 (s, br, 6H, NMe₂), 2.16 (q, 2H, CH₂), 1.15 (t, 3H, CH₃). ¹³C{¹H} NMR ((CD₃)₂SO, δ): 161.89, 159.88 (CH₂C(=N)NH₂ and OC(=N)NMe₂); 121.14 (q, CF₃); 38.17, 37.09 (NMe₂); 24.06 (CH₂); 11.91 (CH₃).

Acknowledgements

The work was supported by the Russian Science Foundation (grant 14-13-00060). The authors thank the Center for X-ray Diffraction Studies, Center for Magnetic Resonance, Center for Chemical Analysis and Materials Research, and Chemistry Educational Centre (all belong to Saint Petersburg State University) for the physicochemical measurements.

References

- (a) D. S. Bolotin, K. I. Kulish, N. A. Bokach, G. L. Starova, V. V. Gurzhiy and V. Y. Kukushkin, *Inorg. Chem.*, 2014, **53**, 10312–10324; (b) J. K. Augustine, V. Akabote, S. G. Hegde

- and P. Alagarsamy, *J. Org. Chem.*, 2009, **74**, 5640–5643;
- (c) V. N. Yarovenko, V. K. Taralashvili, I. V. Zavarzin and M. M. Krayushkin, *Tetrahedron*, 1990, **46**, 3941–3952;
- (d) V. N. Yarovenko, B. I. Ugrak, M. M. Krayushkin, V. Z. Shirinyan and I. V. Zavarzin, *Russ. Chem. Bull.*, 1994, **43**, 627–629; (e) V. N. Yarovenko, I. V. Zavarzin and M. M. Krayushkin, *Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1986, **35**, 1106.
- 2 O. B. Rajesh, D. Bashir, P. Vidya and F. Mazahar, *Mini-Rev. Med. Chem.*, 2014, **14**, 355–369.
 - 3 C. G. Fortuna, R. Berardozi, C. Bonaccorso, G. Caltabiano, L. Di Bari, L. Goracci, A. Guarcello, A. Pace, A. Palumbo Piccionello, G. Pescitelli, P. Pierro, E. Lonati, A. Bulbarelli, C. E. A. Cocuzza, G. Musumarra and R. Musumeci, *Bioorg. Med. Chem.*, 2014, **22**, 6814–6825.
 - 4 M. Chang, Sh. Mobashery, E. Spink, D. Ding, S. Testero, E. Leemans and M. Boudreau, WO2016049586A2, 2016.
 - 5 J. M. dos Santos Filho, D. M. A. de Queiroz e Silva, T. S. Macedo, H. M. P. Teixeira, D. R. M. Moreira, S. Challal, J.-L. Wolfender, E. F. Queiroz and M. B. P. Soares, *Bioorg. Med. Chem.*, 2016, **24**, 5693–5701.
 - 6 (a) C. V. Maftai, E. Fodor, P. G. Jones, C. G. Daniliuc, M. H. Franz, G. Kelter, H.-H. Fiebig, M. Tamm and I. Neda, *Tetrahedron*, 2016, **72**, 1185–1199; (b) K. Challa, M. V. Bhargavi and G. L. D. Krupadanam, *J. Asian Nat. Prod. Res.*, 2016, **18**, 1158–1168; (c) K. N. Nandeesh, H. A. Swarup, N. C. Sandhya, C. D. Mohan, C. S. Pavan Kumar, M. N. Kumara, K. Mantelingu, S. Ananda and K. S. Rangappa, *New J. Chem.*, 2016, **40**, 2823–2828.
 - 7 M. Mohammadi-Khanaposhtani, M. Shabani, M. Faizi, I. Aghaei, R. Jahani, Z. Sharafi, N. Shamsaei Zafarghandi, M. Mahdavi, T. Akbarzadeh, S. Emami, A. Shafiee and A. Foroumadi, *Eur. J. Med. Chem.*, 2016, **112**, 91–98.
 - 8 (a) P. G. N. Sasikumar, M. Ramachandra, A. Prasad and S. S. S. Naremaddepalli, WO2016142886A2, 2016; (b) P. G. N. Sasikumar, M. Ramachandra and S. S. S. Naremaddepalli, WO2016142833A1, 2016.
 - 9 S. K. Jain and J. Nandan, *World J. Pharm. Pharm. Sci.*, 2014, **3**, 762–773, 712 p.
 - 10 W. Zhu, X. Bao, H. Ren, P. Liao, W. Zhu, Y. Yan, L. Wang and Z. Chen, *Clin. Exp. Hypertens.*, 2016, **38**, 435–442.
 - 11 D. V. Ziolkovskiy, V. V. Lipson, A. D. Nikitina and V. A. Chebanov, *Lett. Drug Des. Discovery*, 2016, **13**, 226–233.
 - 12 Y. Cao, C. Min, S. Acharya, K.-M. Kim and S. H. Cheon, *Bioorg. Med. Chem.*, 2016, **24**, 191–200.
 - 13 M. Donnier-Marechal, D. Goyard, V. Folliard, T. Docsa, P. Gergely, J.-P. Praly and S. Vidal, *Beilstein J. Org. Chem.*, 2015, **11**, 499–503.
 - 14 (a) I. Zahanich, I. Kondratov, V. Naumchyk, Y. Kheylik, M. Platonov, S. Zozulya and M. Krasavin, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3105–3111; (b) A. Tolmachev, A. V. Bogolubsky, S. E. Pipko, A. V. Grishchenko, D. V. Ushakov, A. V. Zhemera, O. O. Viniychuk, A. I. Konovets, O. A. Zaporozhets, P. K. Mykhailiuk and Y. S. Moroz, *ACS Comb. Sci.*, 2016, **18**, 616–624.
 - 15 (a) E. Giroto, I. H. Bechtold and H. Gallardo, *Liq. Cryst.*, 2016, **43**, 1768–1777; (b) I. H. R. Tomi, M. M. Abdul Razzaq Al-Obaidey and A. H. R. Al-Daraji, *Liq. Cryst.*, 2016, DOI: 10.1080/02678292.2016.1225837; (c) M. Subrao, D. M. Potukuchi, G. S. Ramachandra, P. Bhagavath, S. G. Bhat and S. Maddasani, *Beilstein J. Org. Chem.*, 2015, **11**, 233–241, 239 p.
 - 16 D. Ko, H. A. Patel and C. T. Yavuz, *Chem. Commun.*, 2015, **51**, 2915–2917.
 - 17 V. Thottempudi, J. Zhang, C. He and J. M. Shreeve, *RSC Adv.*, 2014, **4**, 50361–50364.
 - 18 K. I. Kulish, A. S. Novikov, P. M. Tolstoy, D. S. Bolotin, N. A. Bokach, A. A. Zolotarev and V. Y. Kukushkin, *J. Mol. Struct.*, 2016, **1111**, 142–150.
 - 19 D. S. Bolotin, N. A. Bokach and V. Y. Kukushkin, *Coord. Chem. Rev.*, 2016, **313**, 62–93.
 - 20 (a) E. Tilvez, G. I. Cárdenas-Jirón, M. I. Menéndez and R. López, *Inorg. Chem.*, 2015, **54**, 1223–1231; (b) K. L. Breno, M. D. Pluth, C. W. Landorf and D. R. Tyler, *Organometallics*, 2004, **23**, 1738–1746.
 - 21 (a) P. E. Hansen, *Molecules*, 2015, **20**, 2405–2424; (b) A. Nowroozi, S. Rahmani, A. Eshraghi and K. Shayan, *Struct. Chem.*, 2016, **27**, 829–838; (c) M. P. Romero-Fernandez, M. Avalos, R. Babiano, P. Cintas, J. L. Jimenez and J. C. Palacios, *Tetrahedron*, 2016, **72**, 95–104; (d) D. Rusinska-Roszak, *J. Phys. Chem. A*, 2015, **119**, 3674–3687; (e) M. Vatanparast and A. R. Nekoei, *Struct. Chem.*, 2015, **26**, 1039–1048; (f) *Non-covalent Interactions in the Synthesis and Design of New Compounds*, ed. A. M. Maharramov, K. T. Mahmudov, M. N. Kopylovich, and A. J. L. Pombeiro, Wiley, 2016; (g) K. T. Mahmudov, M. N. Kopylovich and A. J. L. Pombeiro, *Coord. Chem. Rev.*, 2013, **257**, 1244–1281; (h) M. N. Kopylovich, M. F. C. Guedes da Silva, L. M. D. R. S. Martins, M. L. Kouznetsov, K. T. Mahmudov and A. J. L. Pombeiro, *Polyhedron*, 2013, **50**, 374–382; (i) K. T. Mahmudov, M. N. Kopylovich, M. F. C. Guedes da Silva, G. S. Mahmudova, M. Sutradhar and A. J. L. Pombeiro, *Polyhedron*, 2013, **60**, 78–84; (j) M. N. Kopylovich, A. C. C. Nunes, K. T. Mahmudov, M. Haukka, T. C. O. Mac Leod, L. M. D. R. S. Martins, M. L. Kuznetsov and A. J. L. Pombeiro, *Dalton Trans.*, 2011, **40**, 2822–2836; (k) S. Wanninger, V. Lorenz, A. Subhan and F. T. Edelmann, *Chem. Soc. Rev.*, 2015, **44**, 4986–5002; (l) A. B. Davis, R. E. Lambert, F. R. Fronczek, P. J. Cragg and K. J. Wallace, *New J. Chem.*, 2014, **38**, 4678–4683; (m) X. Su, T. F. Robbins and I. Aprahamian, *Angew. Chem., Int. Ed.*, 2011, **50**, 1841–1844; (n) K. T. Mahmudov, M. N. Kopylovich, M. F. C. Guedes da Silva and A. J. L. Pombeiro, *ChemPlusChem*, 2014, **79**, 1523–1531; (o) K. T. Mahmudov, M. F. C. Guedes da Silva, M. Sutradhar, M. N. Kopylovich, F. E. Huseynov, N. T. Shamilov, A. A. Voronina, T. M. Buslaeva and A. J. L. Pombeiro, *Dalton Trans.*, 2015, **44**, 5602–5610; (p) K. T. Mahmudov, M. N. Kopylovich, A. Sabbatini, M. G. B. Drew, L. M. D. R. S. Martins, C. Pettinari and A. J. L. Pombeiro, *Inorg. Chem.*, 2014, **53**, 9946–9958; (q) M. N. Kopylovich, K. T. Mahmudov, A. Mizar and A. J. L. Pombeiro, *Chem. Commun.*, 2011, **47**, 7248–7250; (r) M. N. Kopylovich, A. Mizar, M. F. C. Guedes da Silva, T. C. O. Mac Leod, K. T. Mahmudov and A. J. L. Pombeiro, *Chem. – Eur. J.*, 2013, **19**, 588–600.
 - 22 D. S. Bolotin, V. K. Burianova, A. S. Novikov, M. Y. Demakova, C. Pretorius, P. P. Mokolokolo, A. Roodt, N. A. Bokach,

- V. V. Suslonov, A. P. Zhdanov, K. Y. Zhizhin, N. T. Kuznetsov and V. Y. Kukushkin, *Organometallics*, 2016, **35**, 3612–3623.
- 23 F. H. Allen, O. Kennard, D. G. Watson, L. Brammer and G. Orpen, *J. Chem. Soc., Perkin Trans. 2*, 1987, S1–S19.
- 24 (a) L. Zhu, D. Liu, L. Wu, W. Feng, X. Zhang, J. Wu, D. Fan, X. Lü, R. Lu and Q. Shi, *Inorg. Chem. Commun.*, 2013, **37**, 182–185; (b) D. Dey, G. Kaur, A. Ranjani, L. Gayathri, P. Chakraborty, J. Adhikary, J. Pasan, D. Dhanasekaran, A. R. Choudhury, M. A. Akbarsha, N. Kole and B. Biswas, *Eur. J. Inorg. Chem.*, 2014, 3350–3358; (c) R. Olejník, M. Bílek, Z. Růžicková, Z. Hošťálek, J. Merna and A. Růžicka, *J. Organomet. Chem.*, 2015, **794**, 237–246.
- 25 E. G. Witte, K. S. Schwochau, G. Henkel and B. Krebs, *Inorg. Chim. Acta*, 1984, **94**, 323–331.
- 26 L. Xian, G. Tian, C. M. Beavers, S. J. Teat and D. K. Shuh, *Angew. Chem., Int. Ed.*, 2016, **55**, 4671–4673.
- 27 D. Lefevre-Groboillot, S. Dijols, J.-L. Boucher, J.-P. Mahy, R. Ricoux, A. Desbois, J.-L. Zimmermann and D. Mansuy, *Biochemistry*, 2001, **40**, 9909–9917.
- 28 S.-G. Roh, A. Proust, P. Gouzerh and F. Robert, *J. Chem. Soc., Chem. Commun.*, 1993, 836–838.
- 29 R. G. Pearson, *J. Am. Chem. Soc.*, 1963, **85**, 3533–3539.
- 30 (a) A. G. Orpen, L. Brammer, F. H. Allen, O. Kennard, D. G. Watson and R. Taylor, *J. Chem. Soc., Dalton Trans.*, 1989, **12**, S1–S83; (b) K. F. Konidaris, V. Bekiari, E. Katsoulakou, C. P. Raptopoulou, V. Psycharis, S. P. Perlepes, T. C. Stamatatos and E. Manessi-Zoupa, *Inorg. Chim. Acta*, 2011, **376**, 470–478; (c) K. F. Konidaris, M. Giouli, C. P. Raptopoulou, V. Psycharis, I. I. Verginadis, A. Vasiliadis, A. S. Afendra, S. Karkabounas, E. Manessi-Zoupa and T. C. Stamatatos, *Inorg. Chim. Acta*, 2013, **396**, 49–59.
- 31 J. Ran and Y.-P. Tong, *Struct. Chem.*, 2011, **22**, 1113–1118.
- 32 M. Werner, J. Berner and P. G. Jones, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, 1996, **52**, 72–74.
- 33 M. Y. Demakova, D. S. Bolotin, N. A. Bokach, G. L. Starova and V. Y. Kukushkin, *Inorg. Chim. Acta*, 2015, **425**, 114–117.
- 34 R. F. W. Bader, *Chem. Rev.*, 1991, **91**, 893–928.
- 35 (a) A. S. Mikherdov, M. A. Kinzhalov, A. S. Novikov, V. P. Boyarskiy, I. A. Boyarskaya, D. V. Dar'in, G. L. Starova and V. Y. Kukushkin, *J. Am. Chem. Soc.*, 2016, **138**, 14129–14137; (b) A. S. Novikov, M. L. Kuznetsov and A. J. L. Pombeiro, *Chem. – Eur. J.*, 2013, **19**, 2874–2888; (c) V. N. Mikhaylov, V. N. Sorokoumov, K. A. Korvinson, A. S. Novikov and I. A. Balova, *Organometallics*, 2016, **35**, 1684–1697; (d) X. Ding, M. J. Tuikka, P. Hirva, V. Y. Kukushkin, A. S. Novikov and M. Haukka, *CrystEngComm*, 2016, **18**, 1987–1995; (e) D. M. Ivanov, A. S. Novikov, G. L. Starova, M. Haukka and V. Y. Kukushkin, *CrystEngComm*, 2016, **18**, 5278–5286; (f) T. V. Serebryanskaya, A. S. Novikov, P. V. Gushchin, M. Haukka, R. E. Asfin, P. M. Tolstoy and V. Y. Kukushkin, *Phys. Chem. Chem. Phys.*, 2016, **18**, 14104–14112.
- 36 T. Steiner, *Angew. Chem., Int. Ed.*, 2002, **41**, 48–76.
- 37 D. Roca-Lopez, A. Daru, T. Tejero and P. Merino, *RSC Adv.*, 2016, **6**, 22161–22173.
- 38 (a) L. L. Anderson, *Asian J. Org. Chem.*, 2016, **5**, 9–30; (b) A. Badoiu, G. Bernardinelli, J. Mareda, E. P. Kundig and F. Viton, *Chem. – Asian J.*, 2008, **3**, 1298–1311; (c) N. A. Bokach, M. L. Kuznetsov and V. Y. Kukushkin, *Coord. Chem. Rev.*, 2011, **255**, 2946–2967; (d) L. Maiuolo and A. De Nino, in *Targets in Heterocyclic Systems: Chemistry and Properties*, ed. O. A. Attanasi, P. Merino and D. Spinelli, 2015, vol. 19, pp. 299–345; (e) V. Nair and T. D. Suja, *Tetrahedron*, 2007, **63**, 12247–12275; (f) H. Pellissier, *Tetrahedron*, 2007, **63**, 3235–3285; (g) W. M. Shi, X. P. Ma, G. F. Su and D. L. Mo, *Org. Chem. Front.*, 2016, **3**, 116–130; (h) H. Suga and N. Hayashi, in *Heterocyclic Supramolecules II*, ed. K. Matsumoto, 2009, vol. 18, pp. 119–154.
- 39 (a) R. Sustmann, *Tetrahedron Lett.*, 1971, **12**, 2717–2720; (b) R. Sustmann, *Pure Appl. Chem.*, 1974, **40**, 569–593; (c) R. Sustmann, *Tetrahedron Lett.*, 1971, **12**, 2721–2724.
- 40 (a) T. A. Steitz and J. A. Steitz, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 6496; (b) V. Y. Kukushkin and A. J. L. Pombeiro, *Inorg. Chim. Acta*, 2005, **358**, 1–21.
- 41 (a) L. Palatinus and G. Chapuis, *J. Appl. Crystallogr.*, 2007, **40**, 786–790; (b) L. Palatinus and A. van der Lee, *J. Appl. Crystallogr.*, 2008, **41**, 975–984; (c) L. Palatinus, S. J. Prathapa and S. van Smaalen, *J. Appl. Crystallogr.*, 2012, **45**, 575–580.
- 42 G. M. Sheldrick, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2015, **C71**, 3–8.
- 43 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 44 K. Marakchi, O. K. Kabbaj and N. Komiha, *J. Fluorine Chem.*, 2002, **114**, 81–89.
- 45 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. J. A. Montgomery, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, *Gaussian 09, Revision A.01*, Gaussian, Inc., Wallingford CT, 2009.
- 46 T. Lu and F. Chen, *J. Comput. Chem.*, 2012, **33**, 580–592.
- 47 E. D. Glendening, C. R. Landis and F. Weinhold, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2012, **2**, 1–42.